US EditionTranslational Science Reshaping the 2025 PNS Annual Meeting Agenda: Kathrin Doppler, MD; Vincent Timmerman, PhD, MSc
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
Translational Science Reshaping the 2025 PNS Annual Meeting Agenda: Kathrin Doppler, MD; Vincent Timmerman, PhD, MSc
A pair of committee chairs for the Peripheral Nerve Society’s Annual Meeting discussed how this year’s meeting reflects a growing emphasis on therapeutic research and translational progress in peripheral neuropathies. [WATCH TIME: 2 minutes]
Hansa Biopharma data demonstrates potential of imlifidase in Guillain-Barré syndrome - Pharmafile
Hansa Biopharma will present data from its 15-HMedIdeS-09 phase 2 study of imlifidase for treating Guillain-Barré syndrome (GBS) at the Peripheral Nerve Society (PNS) Annual Meeting, taking place 17 to 20 May in Edinburgh, Scotland. This follows successful outcomes of the phase 2 study of the drug, accelerating its development as a treatment. Shahram Attarian, […] The post Hansa Biopharma data demonstrates potential of imlifidase in Guillain-Bar…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
